Condition
Arthrofibrosis
Total Trials
5
Recruiting
0
Active
1
Completed
2
Success Rate
66.7%-20% vs avg
Key Insights
Highlights
Success Rate
67% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 52/100
Termination Rate
20.0%
1 terminated out of 5 trials
Success Rate
66.7%
-19.8% vs benchmark
Late-Stage Pipeline
40%
2 trials in Phase 3/4
Results Transparency
0%
0 of 2 completed with results
Key Signals
67% success
Data Visualizations
Phase Distribution
4Total
Not Applicable (2)
P 4 (2)
Trial Status
Completed2
Active Not Recruiting1
Terminated1
Withdrawn1
Trial Success Rate
66.7%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT03598829Completed
A Prospective Clinical Trial Comparing Serum Mast Cell Tryptase (SMCT) Levels to Arthrofibrosis Rates Among Primary Total Knee Arthroplasty (TKA) Patients
NCT04082533Phase 4Active Not Recruiting
Intravenous (IV) Hydrocortisone for TKA (Total Knee Arthroplasty)
NCT04360928Not ApplicableTerminated
Knee Split Comparison After ACL Reconstruction
NCT05157464Phase 4WithdrawnPrimary
Losartan Use to Mitigate Arthrofibrosis Following Total Join Arthroplasty
NCT04019847Not ApplicableCompletedPrimary
STAK Tool for Treatment of Arthrofibrosis Post Total Knee Replacement
Showing all 5 trials